heme oxygenase 1

Overview

Heme oxygenase 1 (HO-1), encoded by HMOX1, is an inducible stress-response enzyme that catalyzes the degradation of heme into biologically active products, including biliverdin, carbon monoxide, and free iron. It is widely regarded as a cytoprotective molecule because its expression is strongly upregulated by oxidative stress, inflammation, and other cellular insults. In many tissues, HO-1 functions as part of the antioxidant defense network downstream of nuclear factor erythroid 2-related factor 2 (Nrf2) and its negative regulator kelch like ECH associated protein 1 (KEAP1), helping cells adapt to redox imbalance and injury.

Biomedically, HO-1 is frequently studied in contexts involving oxidative stress, reactive oxygen species, ferroptosis, and inflammatory signaling pathways such as nuclear factor kappa B. Because of this, it is often examined as a mechanistic target or biomarker in diseases including ischemic injury, kidney disease, neurodegeneration-related dysfunction, and cancer. In experimental studies, increased HO-1 expression is commonly interpreted as evidence of activation of antioxidant programs, often alongside Nrf2, NQO1, and related protective pathways.

Recent Publications Summary

Recent studies have repeatedly implicated heme oxygenase 1 (HO-1) as a downstream effector in antioxidant and cytoprotective signaling, especially in models of oxidative stress, ferroptosis, and tissue injury. In a mouse model of type 2 diabetes-associated cognitive dysfunction, isoorientin improved glucose metabolism, cognitive performance, synaptic protein expression, apoptosis markers, and brain oxidative stress, while mechanistic analysis included GSK3β activity and the expression of Nrf2 and HO-1 42467274Jul. In a rat model of oxaliplatin-induced chemobrain, thymol nanoparticles were reported to improve cognitive impairment and histopathological injury, with the study specifically examining Nrf2/HO-1 signaling alongside endoplasmic reticulum stress and NLRP3 inflammasome pathways 42202464May. Similarly, poliumoside alleviated ischemic stroke injury in cells and mice by reducing reactive oxygen species, apoptosis, and mitochondrial dysfunction, and was shown to activate the Keap1/Nrf2 pathway with upregulation of HO-1 and NQO1 42134761May.

HO-1 also emerged as a key node in ferroptosis-related cancer studies. DMAMCL induced ferroptosis in neuroblastoma in vitro and in vivo, upregulated HMOX1, and required HMOX1 for ferroptotic effects in MYCN-amplified cells; the study further showed that DMAMCL bound KEAP1, increased nuclear NRF2, and drove HMOX1 expression in the MYCN-amplified subtype 42444025Jul. In gastric cancer, noni fruit juice was reported to suppress tumor progression and induce ferroptosis through the Nrf2/HO-1-GPX4 axis 42132559May. In cerebral ischemia/reperfusion injury, salvianolic acid B reduced infarct volume and neurological deficits while suppressing ACSL4 and TFR1, enhancing Nrf2 nuclear translocation, and increasing downstream HO-1 and GPX4 expression 42186809May. These findings collectively place HO-1 within a broader Nrf2-centered ferroptosis-suppressive network across neurological and oncologic models.

Additional studies linked HO-1 to protection in diabetic, renal, and inflammatory settings. Acupuncture combined with Warm Kidney and Spleen Granules improved diabetic diarrhea and was associated with activation of Nrf2/HO-1 signaling alongside reduced oxidative stress, inflammation, and intestinal barrier dysfunction 42105678May. Eriodictyol alleviated diabetic limb ischemia/reperfusion injury and was reported to upregulate Nrf2/HO-1 while reducing oxidative injury and apoptosis 42090904May. In membranous nephropathy rats, ferroptosis inhibition reduced proteinuria and renal damage and restored Nrf2/HO-1 expression 42044765Apr. Across these publications, HO-1 was most often studied as part of Nrf2-dependent antioxidant responses, with reported associations to reduced oxidative stress, ferroptosis suppression, and improved tissue function 42467274Jul42202464May42134761May42444025Jul42132559May42186809May42105678May42090904May42044765Apr.

What Changes, What Holds

1. HO-1 remains a downstream antioxidant and cytoprotective node in injury models, but the new studies do not move it beyond the established Nrf2-centered framework
REINFORCES These reports keep HO-1 in the same interpretive lane as the Overview: a readout and mediator of stress-adaptive signaling, with reduced oxidative injury and improved tissue function tracking with Nrf2/HO-1 activation 42467274Jul42202464May42134761May. They sharpen the breadth of contexts in which that baseline holds, but they do not challenge the idea that HO-1 is mainly a stress-response effector.

2. HO-1 is further supported as a ferroptosis-linked effector, not a replacement for the established antioxidant account
REINFORCES The cancer and ischemia studies extend the existing link between HO-1, Nrf2, and ferroptosis suppression, showing that HMOX1 can sit inside a pro-death or anti-death ferroptotic circuit depending on context 42444025Jul42132559May42186809May. That strengthens the Overview’s framing of HO-1 as a mechanistic node in oxidative stress biology, while leaving unsettled how often HO-1 is causal versus merely co-induced with broader Nrf2 activity.

3. HO-1 continues to track tissue protection across metabolic, renal, and inflammatory injury settings
REINFORCES These studies broaden the disease settings in which HO-1 rises with improved redox balance, reduced apoptosis, and better organ function, but they do not assign it a new role outside the Overview’s antioxidant-defense model 42105678May42090904May42044765Apr. The main consequence is confirmatory: HO-1 remains a common downstream marker and likely mediator of protective responses, especially where ferroptosis inhibition and Nrf2 activation overlap.

Overview update candidates: none.